| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus B Komoroski, N Vachharajani, Y Feng, L Li, D Kornhauser, M Pfister Clinical Pharmacology & Therapeutics 85 (5), 513-519, 2009 | 520 | 2009 |
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects B Komoroski, N Vachharajani, D Boulton, D Kornhauser, M Geraldes, L Li, ... Clinical Pharmacology & Therapeutics 85 (5), 520-526, 2009 | 473 | 2009 |
| Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes RA DeFronzo, M Hompesch, S Kasichayanula, X Liu, Y Hong, M Pfister, ... Diabetes care 36 (10), 3169-3176, 2013 | 367 | 2013 |
| Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight L Zhang, Y Feng, J List, S Kasichayanula, M Pfister Diabetes, Obesity and Metabolism 12 (6), 510-516, 2010 | 256 | 2010 |
| Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade P Ferrari, HP Marti, M Pfister, FJ Frey Journal of hypertension 20 (1), 125-130, 2002 | 189 | 2002 |
| Differential immunodiagnosis between cystic hydatid disease and other cross-reactive pathologies. D Poretti, E Felleisen, F Grimm, M Pfister, F Teuscher, C Zuercher, ... The American journal of tropical medicine and hygiene 60 (2), 193-198, 1999 | 187 | 1999 |
| Effect of kidney function on drug kinetics and dosing in neonates, infants, and children F Rodieux, M Wilbaux, JN van den Anker, M Pfister Clinical pharmacokinetics 54, 1183-1204, 2015 | 161 | 2015 |
| Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398 M Pfister, L Labbé, SM Hammer, J Mellors, KK Bennett, S Rosenkranz, ... Antimicrobial agents and chemotherapy 47 (1), 130-137, 2003 | 157 | 2003 |
| The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus S Kasichayanula, X Liu, M Pe Benito, M Yao, M Pfister, FP LaCreta, ... British journal of clinical pharmacology 76 (3), 432-444, 2013 | 142 | 2013 |
| Daptomycin is highly efficacious against penicillin-resistant and penicillin-and quinolone-resistant pneumococci in experimental meningitis P Cottagnoud, M Pfister, F Acosta, M Cottagnoud, L Flatz, F Kühn, ... Antimicrobial agents and chemotherapy 48 (10), 3928-3933, 2004 | 132 | 2004 |
| Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose TA Leil, Y Feng, L Zhang, A Paccaly, P Mohan, M Pfister CliniCal pharmaCology & TherapeuTiCs 88 (3), 375-382, 2010 | 116 | 2010 |
| Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium–glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy … S Kasichayanula, X Liu, WC Shyu, W Zhang, M Pfister, SC Griffen, T Li, ... Diabetes, Obesity and Metabolism 13 (1), 47-54, 2011 | 112 | 2011 |
| Model‐based meta‐analysis for comparative efficacy and safety: application in drug development and beyond JW Mandema, M Gibbs, RA Boyd, DR Wada, M Pfister Clinical Pharmacology & Therapeutics 90 (6), 766-769, 2011 | 108 | 2011 |
| Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study S Kasichayanula, X Liu, W Zhang, M Pfister, FP LaCreta, DW Boulton Clinical therapeutics 33 (11), 1798-1808, 2011 | 107 | 2011 |
| Concepts and challenges in quantitative pharmacology and model-based drug development L Zhang, M Pfister, B Meibohm The AAPS journal 10, 552-559, 2008 | 107 | 2008 |
| Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers WK Fenske, I Schnyder, G Koch, C Walti, M Pfister, P Kopp, M Fassnacht, ... The Journal of Clinical Endocrinology & Metabolism 103 (2), 505-513, 2018 | 104 | 2018 |
| Pharmacometric approaches to personalize use of primarily renally eliminated antibiotics in preterm and term neonates M Wilbaux, A Fuchs, J Samardzic, F Rodieux, C Csajka, K Allegaert, ... The Journal of Clinical Pharmacology 56 (8), 909-935, 2016 | 83 | 2016 |
| Artificial intelligence and machine learning applied at the point of care Z Angehrn, L Haldna, AS Zandvliet, E Gil Berglund, J Zeeuw, B Amzal, ... Frontiers in pharmacology 11, 759, 2020 | 79 | 2020 |
| Physiologically based pharmacokinetic modeling in pregnancy: a systematic review of published models A Dallmann, M Pfister, J van den Anker, T Eissing Clinical Pharmacology & Therapeutics 104 (6), 1110-1124, 2018 | 72 | 2018 |
| Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative C Daniel, R Ziswiler, B Frey, M Pfister, HP Marti Experimental nephrology 8 (1), 52-62, 2000 | 71 | 2000 |
Van Den Anker JProfessor of Pediatrics, George Washington UniversityDirección de correo verificada de cnmc.org
